(Q38523788)

3 September 2017

Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide (English)

1 reference

3 September 2017

S Ricci

1

1 reference

3 September 2017

A Antonuzzo

2

1 reference

3 September 2017

L Galli

3

1 reference

3 September 2017

M Ferdeghini

4

1 reference

3 September 2017

L Bodei

5

1 reference

3 September 2017

C Orlandini

6

1 reference

3 September 2017

P F Conte

7

1 reference

3 September 2017

1 September 2000

1 reference

3 September 2017

1 reference

3 September 2017

11

1 reference

3 September 2017

1127-1130

1 reference

3 September 2017

9

1 reference

The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors

3 September 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

1 reference

7 January 2021

Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008383132024

7 January 2021

Identifiers

DOI

10.1023/A:1008383132024

1 reference

3 September 2017

1 reference